Illumina, Inc. $ILMN Shares Acquired by Meiji Yasuda Life Insurance Co

30 Aug 2026, 10:27 by Sarita Garza · The Markets Daily

Meiji Yasuda Life Insurance Co increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 182.5% in the second quarter, Holdings Channel.com reports. The institutional investor owned 5,464 shares of the life sciences company’s stock after acquiring an additional 3,530 shares during the period. Meiji Yasuda Life Insurance Co’s holdings in Illumina were worth $961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the stock. Elyxium Wealth LLC bought a new stake in Illumina in the fourth quarter valued at $25,000. Laurel Wealth Advisors LLC bought a new position in shares of Illumina during the fourth quarter worth about $26,000. Fiduciary Financial Advisors bought a new position in shares of Illumina during the second quarter worth about $26,000. Activest Wealth Management increased its holdings in shares of Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 215 shares during the period. Finally, Keating Financial Advisory Services Inc. bought a new stake in Illumina in the 2nd quarter valued at about $32,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president directly owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 138,379 shares of Illumina stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $228.89, for a total value of $31,673,569.31. Following the transaction, the director owned 1,033,910 shares in the company, valued at approximately $236,651,659.90. This trade represents a 11.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,034,688 shares of company stock worth $417,970,281 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Illumina Stock Down 5.3%

ILMN stock opened at $215.59 on Friday. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $231.81. The company has a market capitalization of $32.55 billion, a price-to-earnings ratio of 40.22, a price-to-earnings-growth ratio of 3.03 and a beta of 1.45. The firm’s 50-day moving average is $194.05 and its two-hundred day moving average is $155.60. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period last year, the firm posted $1.19 earnings per share. The business’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on ILMN shares. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a report on Friday, July 31st. TD Cowen raised their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Finally, Canaccord Genuity Group lifted their target price on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $188.40.

Read Our Latest Research Report on ILMN

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

About Illumina

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.